Restless Legs Syndrome - Pipeline Review, H1 2019
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Restless Legs Syndrome - Pipeline Review, H1 2019
Summary
Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Restless Legs Syndrome - Pipeline Review, H1 2019, provides an overview of the Restless Legs Syndrome (Central Nervous System) pipeline landscape.
Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a disorder of the part of the nervous system that affects the legs and causes an urge to move them. Symptoms include itching, pain, a creepy-crawly feeling and cramping in the calfs or legs. Predisposing factor includes age. Treatment includes muscle relaxants, sleep medications and narcotic medications.
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Restless Legs Syndrome - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Restless Legs Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Restless Legs Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Restless Legs Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 2 and 2 respectively.
Restless Legs Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Restless Legs Syndrome (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Restless Legs Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Restless Legs Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Restless Legs Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Restless Legs Syndrome (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Restless Legs Syndrome (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Restless Legs Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Summary
Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Restless Legs Syndrome - Pipeline Review, H1 2019, provides an overview of the Restless Legs Syndrome (Central Nervous System) pipeline landscape.
Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a disorder of the part of the nervous system that affects the legs and causes an urge to move them. Symptoms include itching, pain, a creepy-crawly feeling and cramping in the calfs or legs. Predisposing factor includes age. Treatment includes muscle relaxants, sleep medications and narcotic medications.
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Restless Legs Syndrome - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Restless Legs Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Restless Legs Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Restless Legs Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 2 and 2 respectively.
Restless Legs Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Restless Legs Syndrome (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Restless Legs Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Restless Legs Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Restless Legs Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Restless Legs Syndrome (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Restless Legs Syndrome (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Restless Legs Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
TABLE OF CONTENTS
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Restless Legs Syndrome - Overview
Restless Legs Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Restless Legs Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Restless Legs Syndrome - Companies Involved in Therapeutics Development
Axim Biotechnologies Inc
Bioprojet SCR
Hisamitsu Pharmaceutical Co Inc
Merz Pharma GmbH & Co KgaA
Omeros Corp
Relmada Therapeutics Inc
Serina Therapeutics Inc
Vifor Pharma Ltd
Restless Legs Syndrome - Drug Profiles
(cannabidiol + dronabinol) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(cannabidiol + gabapentin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aplindore fumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BP-1.4979 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ferric carboxymaltose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
incobotulinumtoxin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLS-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REL-1017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ropinirole hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SER-214 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Restless Legs Syndrome - Dormant Projects
Restless Legs Syndrome - Discontinued Products
Restless Legs Syndrome - Product Development Milestones
Featured News & Press Releases
Oct 23, 2014: Hisamitsu Announces the results of Phase II clinical study of HP-3000 in Japan (a transdermal system for the treatment of idiopathic restless legs syndrome)
Oct 16, 2008: Neurogen Announces Positive Top-Line Results From Two Phase II Trials For Aplindore In Restless Legs Syndrome And Parkinsons Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List Of Tables
Number of Products under Development for Restless Legs Syndrome, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Restless Legs Syndrome - Pipeline by Axim Biotechnologies Inc, H1 2019
Restless Legs Syndrome - Pipeline by Bioprojet SCR, H1 2019
Restless Legs Syndrome - Pipeline by Hisamitsu Pharmaceutical Co Inc, H1 2019
Restless Legs Syndrome - Pipeline by Merz Pharma GmbH & Co KgaA, H1 2019
Restless Legs Syndrome - Pipeline by Omeros Corp, H1 2019
Restless Legs Syndrome - Pipeline by Relmada Therapeutics Inc, H1 2019
Restless Legs Syndrome - Pipeline by Serina Therapeutics Inc, H1 2019
Restless Legs Syndrome - Pipeline by Vifor Pharma Ltd, H1 2019
Restless Legs Syndrome - Dormant Projects, H1 2019
Restless Legs Syndrome - Discontinued Products, H1 2019
List Of Figures
Number of Products under Development for Restless Legs Syndrome, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019
RELATED REPORTS
Restless Legs Syndrome - Market Insight, Epidemiology and Market Forecast - 2028
Restless Legs Syndrome - Market Insight, Epidemiology and Market Forecast - 2028 report provides a detailed analysis of the Restless Legs Syndrome epidemiology and market outlook for
View ReportRestless Legs Syndrome - Epidemiology Forecast to 2028
Restless Legs Syndrome - Epidemiology Forecast, 2028 report provides a comprehensive analysis of the Restless Legs Syndrome epidemiology, providing the historical and forecasted data for
View ReportCOVID-19 Outbreak-Global Restless Legs Syndrome Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020
The Restless Legs Syndrome market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025.Under COVID-19 outbreak globally,
View ReportRestless Legs Syndrome - Market Insight, Epidemiology and Market Forecast - 2028
Restless Legs Syndrome - Market Insight, Epidemiology and Market Forecast - 2028 report provides a detailed analysis of the Restless Legs Syndrome epidemiology and market outlook for
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
